Literature DB >> 22027650

PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 19.

Stuart A Scott1, Katrin Sangkuhl, Alan R Shuldiner, Jean-Sébastien Hulot, Caroline F Thorn, Russ B Altman, Teri E Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22027650      PMCID： PMC3349992          DOI： 10.1097/FPC.0b013e32834d4962

Source DB:  PubMed          Journal:  Pharmacogenet Genomics        ISSN： 1744-6872            Impact factor:   2.089


× No keyword cloud information.
  95 in total

1.  High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

Authors:  Jean-Philippe Collet; Jean-Sébastien Hulot; Ghalia Anzaha; Ana Pena; Thomas Chastre; Claire Caron; Johanne Silvain; Guillaume Cayla; Anne Bellemain-Appaix; Jean-Baptiste Vignalou; Sophie Galier; Olivier Barthélémy; Farzin Beygui; Vanessa Gallois; Gilles Montalescot
Journal:  JACC Cardiovasc Interv       Date:  2011-04       Impact factor: 11.195

2.  ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A Report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents.

Authors:  Neena S Abraham; Mark A Hlatky; Elliott M Antman; Deepak L Bhatt; David J Bjorkman; Craig B Clark; Curt D Furberg; David A Johnson; Charles J Kahi; Loren Laine; Kenneth W Mahaffey; Eamonn M Quigley; James Scheiman; Laurence S Sperling; Gordon F Tomaselli
Journal:  J Am Coll Cardiol       Date:  2010-12-07       Impact factor: 24.094

3.  Cytochrome P450 2C19*2 polymorphism and cardiovascular recurrences in patients taking clopidogrel: a meta-analysis.

Authors:  F Sofi; B Giusti; R Marcucci; A M Gori; R Abbate; G F Gensini
Journal:  Pharmacogenomics J       Date:  2010-03-30       Impact factor: 3.550

4.  Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent.

Authors:  Guilherme Suarez-Kurtz
Journal:  Eur J Clin Pharmacol       Date:  2010-10-03       Impact factor: 2.953

Review 5.  Pharmacogenetics: from bench to byte--an update of guidelines.

Authors:  J J Swen; M Nijenhuis; A de Boer; L Grandia; A H Maitland-van der Zee; H Mulder; G A P J M Rongen; R H N van Schaik; T Schalekamp; D J Touw; J van der Weide; B Wilffert; V H M Deneer; H-J Guchelaar
Journal:  Clin Pharmacol Ther       Date:  2011-03-16       Impact factor: 6.875

6.  CYP2C19 variation and citalopram response.

Authors:  David A Mrazek; Joanna M Biernacka; Dennis J O'Kane; John L Black; Julie M Cunningham; Maureen S Drews; Karen A Snyder; Susanna R Stevens; Augustus John Rush; Richard M Weinshilboum
Journal:  Pharmacogenet Genomics       Date:  2011-01       Impact factor: 2.089

Review 7.  Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450-2C19 (CYP2C19) genotype and clopidogrel therapy.

Authors:  S A Scott; K Sangkuhl; E E Gardner; C M Stein; J-S Hulot; J A Johnson; D M Roden; T E Klein; A R Shuldiner
Journal:  Clin Pharmacol Ther       Date:  2011-06-29       Impact factor: 6.875

8.  Isolated and interactive impact of common CYP2C19 genetic variants on the antiplatelet effect of chronic clopidogrel therapy.

Authors:  D Sibbing; D Gebhard; W Koch; S Braun; J Stegherr; T Morath; N Von Beckerath; J Mehilli; A Schömig; T Schuster; A Kastrati
Journal:  J Thromb Haemost       Date:  2010-05-21       Impact factor: 5.824

9.  The relation between CYP2C19 genotype and phenotype in stented patients on maintenance dual antiplatelet therapy.

Authors:  Paul A Gurbel; Alan R Shuldiner; Kevin P Bliden; Kathaleen Ryan; Ruth E Pakyz; Udaya S Tantry
Journal:  Am Heart J       Date:  2011-03       Impact factor: 4.749

10.  Linkage disequilibrium between the CYP2C19*17 allele and wildtype CYP2C8 and CYP2C9 alleles: identification of CYP2C haplotypes in healthy Nordic populations.

Authors:  Rasmus S Pedersen; Charlotte Brasch-Andersen; Sarah C Sim; Troels K Bergmann; Jónrit Halling; Maria S Petersen; Pál Weihe; Hege Edvardsen; Vessela N Kristensen; Kim Brøsen; Magnus Ingelman-Sundberg
Journal:  Eur J Clin Pharmacol       Date:  2010-07-28       Impact factor: 2.953
View more
  61 in total

1.  Escitalopram pharmacogenetics: CYP2C19 relationships with dosing and clinical outcomes in autism spectrum disorder.

Authors:  Jeffrey R Bishop; Fedra Najjar; Leah H Rubin; Stephen J Guter; Thomas Owley; Matthew W Mosconi; Suma Jacob; Edwin H Cook
Journal:  Pharmacogenet Genomics       Date:  2015-11       Impact factor: 2.089

Review 2.  Clopidogrel Resistance in Lower Extremity Arterial Endovascular Interventions.

Authors:  Kyle M Markel; Efthymios D Avgerinos
Journal:  Curr Pharm Des       Date:  2018       Impact factor: 3.116

Review 3.  Antiplatelet drug interactions with proton pump inhibitors.

Authors:  Stuart A Scott; Aniwaa Owusu Obeng; Jean-Sébastien Hulot
Journal:  Expert Opin Drug Metab Toxicol       Date:  2013-11-09       Impact factor: 4.481

Review 4.  The pharmacogenetic control of antiplatelet response: candidate genes and CYP2C19.

Authors:  Yao Yang; Joshua P Lewis; Jean-Sébastien Hulot; Stuart A Scott
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-07-14       Impact factor: 4.481

5.  Impact of CYP3A5 polymorphism on platelet reactivity at percutaneous coronary intervention and after 9 months of aspirin and clopidogrel therapy in Japanese patients with coronary artery disease.

Authors:  Seiji Hokimoto; Tadasuke Chitose; Michio Mizobe; Tomonori Akasaka; Yuichiro Arima; Koichi Kaikita; Satomi Iwashita; Kazunori Morita; Hiroko Miyazaki; Kentaro Oniki; Kunihiko Matsui; Kazuko Nakagawa; Hisao Ogawa
Journal:  Eur J Clin Pharmacol       Date:  2014-04-26       Impact factor: 2.953

6.  An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.

Authors:  Sam Mostafa; Carl M J Kirkpatrick; Keith Byron; Leslie Sheffield
Journal:  J Neural Transm (Vienna)       Date:  2018-09-06       Impact factor: 3.575

7.  A phase 1 study of the c-Met inhibitor, tivantinib (ARQ197) in children with relapsed or refractory solid tumors: A Children's Oncology Group study phase 1 and pilot consortium trial (ADVL1111).

Authors:  James I Geller; John P Perentesis; Xiaowei Liu; Charles G Minard; Rachel A Kudgus; Joel M Reid; Elizabeth Fox; Susan M Blaney; Brenda J Weigel
Journal:  Pediatr Blood Cancer       Date:  2017-04-27       Impact factor: 3.167

8.  Rapid screening for targeted genetic variants via high-resolution melting curve analysis.

Authors:  Allison B Chambliss; Molly Resnick; Athena K Petrides; William A Clarke; Mark A Marzinke
Journal:  Clin Chem Lab Med       Date:  2017-03-01       Impact factor: 3.694

9.  PharmGKB summary: voriconazole pathway, pharmacokinetics.

Authors:  Julia M Barbarino; Aniwaa Owusu Obeng; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2017-05       Impact factor: 2.089

10.  A physiome interoperability roadmap for personalized drug development.

Authors:  Simon Thomas; Katherine Wolstencroft; Bernard de Bono; Peter J Hunter
Journal:  Interface Focus       Date:  2016-04-06       Impact factor: 3.906
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.